SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Incyte (INCY)
INCY 106.00+0.8%Nov 7 9:30 AM EST
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Biotech Jim who wrote (2870)6/13/2013 7:58:25 AM
From: Biotech Jim  Read Replies (3) of 3202
 
And here is the RA data on the Galapagos JAK1 compound GLPG0634 in a 4 week study presented at EULAR:

glpg.com

Here is one thing in the stated data that is a concern, due to the potential need for tox studies on this metabolite as well as the parent compound. Efficacy data is not strong due to the possibility of the treatment period of 4 weeks.

"An active and JAK1-selective metabolite supports the activity of GLPG0634. The lower potency of
the metabolite is compensated by its high exposure in humans. The long half-life of the
metabolite and the resulting high plasma levels when parent GLPG0634 is at trough, provides a
lasting effect. Because of the 7-hour half-life of GLPG0634, both BID and QD regimens were
studied. However, the metabolite contribution to JAK1 inhibition now provides a potential
explanation for the sustained efficacy results observed with once daily dosing of GLPG0634,
adding to convenience for patients."

This certainly complicates the development plan.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News